Compare ATI & RMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATI | RMD |
|---|---|---|
| Founded | 1960 | 1989 |
| Country | United States | United States |
| Employees | 7600 | 10600 |
| Industry | Steel/Iron Ore | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.2B | 28.4B |
| IPO Year | 1996 | N/A |
| Metric | ATI | RMD |
|---|---|---|
| Price | $201.63 | $187.91 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 10 |
| Target Price | $153.75 | ★ $292.56 |
| AVG Volume (30 Days) | ★ 1.7M | 1.4M |
| Earning Date | 04-30-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 1.13% |
| EPS Growth | ★ 11.76 | N/A |
| EPS | ★ 0.85 | N/A |
| Revenue | ★ $4,043,500,000.00 | N/A |
| Revenue This Year | $9.52 | $10.60 |
| Revenue Next Year | $9.02 | $7.41 |
| P/E Ratio | $237.36 | ★ $25.61 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $70.42 | $180.27 |
| 52 Week High | $203.60 | $293.81 |
| Indicator | ATI | RMD |
|---|---|---|
| Relative Strength Index (RSI) | 73.31 | 39.17 |
| Support Level | $141.00 | $180.27 |
| Resistance Level | N/A | $260.21 |
| Average True Range (ATR) | 7.79 | 4.80 |
| MACD | 1.48 | 0.26 |
| Stochastic Oscillator | 93.13 | 42.41 |
ATI Inc supplies specialty metals to various end markets, including aerospace and defense, oil and gas, automotive, and electrical energy, among many others. The company's operating segment includes High-Performance Materials and Components and Advanced Alloys and Solutions. The majority of revenue is from the High-Performance Materials segment. The High-Performance Materials segment is focused on a wide range of high-performance specialty materials, parts, and components for several the majority of end markets, including the aerospace & defense, medical, and energy markets. Geographically, it operates in the United States, China, the United Kingdom, Germany, France, Canada, and Others, the majority is from the United States.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with aging populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.